Dr. Gomella Discusses Immunotherapy in Bladder Cancer

Leonard Gomella, MD
Published: Monday, Apr 10, 2017



Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

Urologists have been using immune-based agents in the urinary tract for 20 to 30 years, making the bladder a natural home for immunotherapy, says Gomella.

Newer studies are focusing on the mechanisms of immunotherapy—determining that it fights cancers. Additionally, Gomella says, newer agents are geared more toward the systemic treatment of patients with advanced bladder cancer rather than localized disease, but those agents are in the pipeline.
 


Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

Urologists have been using immune-based agents in the urinary tract for 20 to 30 years, making the bladder a natural home for immunotherapy, says Gomella.

Newer studies are focusing on the mechanisms of immunotherapy—determining that it fights cancers. Additionally, Gomella says, newer agents are geared more toward the systemic treatment of patients with advanced bladder cancer rather than localized disease, but those agents are in the pipeline.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x